RVX Stock Overview
A late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Resverlogix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.055 |
| 52 Week High | CA$0.095 |
| 52 Week Low | CA$0.04 |
| Beta | 0.82 |
| 11 Month Change | -8.33% |
| 3 Month Change | -38.89% |
| 1 Year Change | -15.38% |
| 33 Year Change | -88.54% |
| 5 Year Change | -95.83% |
| Change since IPO | -96.45% |
Recent News & Updates
Shareholder Returns
| RVX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -8.3% | -8.9% | 1.3% |
| 1Y | -15.4% | -1.9% | 23.1% |
Return vs Industry: RVX underperformed the Canadian Biotechs industry which returned 1.5% over the past year.
Return vs Market: RVX underperformed the Canadian Market which returned 21.7% over the past year.
Price Volatility
| RVX volatility | |
|---|---|
| RVX Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: RVX's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: RVX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 19 | Don McCaffrey | www.resverlogix.com |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications.
Resverlogix Corp. Fundamentals Summary
| RVX fundamental statistics | |
|---|---|
| Market cap | CA$15.44m |
| Earnings (TTM) | -CA$15.68m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs RVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.23m |
| Earnings | -US$11.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -93.0% |
How did RVX perform over the long term?
See historical performance and comparison